ANIP: ANI Pharma P/S Multiple

Brandmark of ANI Pharma (ANIP)

ANI Pharmaceuticals is implementing packaging and encapsulation automation to reduce personnel costs. The company also utilizes third-party contractors for product manufacturing and pharmacy distribution. The current P/S multiple, with GURU.Markets data illustrated on this chart, is characterized by 1.60 setting the current value of the metric. The firm successfully combines the production of generics with the sale of profitable orphan drugs.

ANIP (ANI Pharmaceuticals, Inc.) P/S Multiple history from 07/04/2022 to 11/13/2026

Metric breakdowns and analytics for ANI Pharma (ANIP)

- share price and consensus valuation forecast:
Price Performance Chart anipharmaceuticals.com|ANIP - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization ANI Pharma|ANIP - Total Company Value
- balance sheet equity data:
Equity per Share ANI Pharmaceuticals|ANIP - Book Capitalization|Market Capitalization to Book Value anipharmaceuticals.com|ANIP - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio ANI Pharmaceuticals|ANIP - Long-Term Debt to Equity|Current Liabilities to Equity ANI Pharmaceuticals Corp|ANIP - Company Aggregate Debts|Debt to Net Assets Ratio ANI Pharma|ANIP - Company Long-Term Debts|Company Short-Term Debts ANI Pharmaceuticals|Intermediate Coverage Ratio anipharmaceuticals.com
- net income and valuation multiples indicators:
ANIP - Company Net Income|Future Profit ANI Pharmaceuticals|ANIP - P/E Multiple|Forward P/E Multiple ANI Pharmaceuticals Inc|ANIP - PEG Multiple|Enterprise Value to EBITDA Ratio ANI Pharma|ANIP - Operating profit EBITDA|Net earnings per one share for the last twelve months ANI Pharmaceuticals|ANIP - Net earnings per share for the last 12 months|Quarterly EPS earnings growth anipharmaceuticals.com|ANIP - Net earnings per share growth this year|Projected earnings per share increase next year ANI Pharmaceuticals
- issuer revenue and sales details:
ANIP - Revenue and Sales Volume|Company Future Sales anipharmaceuticals.com|ANIP - P/S Multiple|Forward Price-to-Revenue Multiple ANI Pharma
General company analysis:anipharmaceuticals.com, ANIP
Finished products of ANI Pharmaceuticals Inc

For ANI Pharmaceuticals (ANIP), which combines in-house capacities with GMP-standard outsourced production, the P/S multiple serves as a key tool for evaluating revenue generation efficiency. By analyzing the current P/S valuation, an investor compares market capitalization with actual sales volume, allowing them to filter out speculative noise and determine the fair value of the business relative to its operational scale.

Competing companies

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple KVUE (Kenvue)|P/S Multiple Verona Pharma PLC VRNA|MENS - Price-to-Revenue Ratio|LGND (Ligand Corp) - Market Cap to Revenue Ratio|AMRX: P/S Multiple|PRGO - Price-to-Revenue Coefficient|Market Cap to Revenue ALVO|LQDA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|MNKD: Price-to-Sales Ratio|P/S Multiple AMPH (Amphastar Pharmaceuticals)|Market Capitalization-to-Revenue Ratio PCRX|ARS Pharmaceuticals, Inc. - P/S Multiple|TBPH - P/S Multiple|Aquestive Pharma (AQST) - Price-to-Revenue Ratio|scPharmaceuticals - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Tectonic Therapeutic Inc.|Market Cap to Revenue tonixpharma.com (TNXP)|P/S Multiple SXTC|P/S Multiple eupraxiapharma.com (EPRX)|P/S Multiple BHST (BioHarvest)|EXOZ - Market Cap to Revenue|Oramed Pharma - P/S Multiple|Price to Sales Entera Bio Ltd.|HYFT (MindWalk Holdings Inc.) - Market Cap to Revenue|ABVC BioPharma Inc. (ABVC) - P/S Multiple|Market Cap to Revenue CPIX|QNTM (Quantum BioPharma Corp) - Market Cap to Sales Volume|P/S Multiple FGEN|Price-to-Revenue Coefficient telomirpharma.com|P/S Multiple RANI (Rani Therapeutics Holdings, Inc.)|SNYR - Market Cap to Revenue|Rallybio Corp. - P/S Multiple|LEXX - P/S Multiple|Pulmatrix, Inc. (PULM) - Price-to-Revenue Ratio|PTHL (Pheton Holdings) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Aptorum Group Ltd|Lyra Therapeutics Inc. (LYRA) - Price-to-Revenue Coefficient|P/S Multiple IBO|P/S Multiple tnfpharma.com (TNFA)|Price-to-Revenue Ratio cbdMD YCBD|PRFX: Market Cap to Revenue Ratio|Auris Medical - P/S Multiple|Price-to-Revenue Coefficient Lipella Pharmaceuticals Inc LIPO|Optinose (OPTN) - Price-to-Revenue Ratio|Price-to-Sales Ratio PIRS (Pieris Pharma)|Price-to-Revenue Ratio Procaps Group S.A.|petrospharma.com - Price-to-Sales Ratio|P/S Multiple QLI|SLRN (Acelyrin Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple TFFP (TFF Pharma)